Section Arrow
BLTE.NASDAQ
- Belite Bio
Quotes are at least 15-min delayed:2026/07/17 06:02 EDT
Pre Market
Last
 152
+1.33 (+0.88%)
Bid
143.56
Ask
153.81
High 152 
Low 152 
Volume
Regular Hours (Closed)
Last
 150.67
+1.2 (+0.80%)
Day High 
151.2 
Prev. Close
149.47 
1-M High
158.9 
Volume 
116.25K 
Bid
143.56
Ask
153.81
Day Low
146.62 
Open
151 
1-M Low
136.09 
Market Cap 
5.99B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 149.87 
20-SMA 149.07 
50-SMA 146.78 
52-W High 200 
52-W Low 59.12 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.54/2.34
Enterprise Value
5.99B
Balance Sheet
Book Value Per Share
19.85
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
LIMNLiminatus Pharma Inc0.1477+0.0332+29.00%-- 
Pre Market 0.1263 -0.0214 -14.49%
ATAIAtaiBeckley Inc7.15+1.79+33.40%-- 
Pre Market 7.08 -0.07 -0.98%
KAPAKairos Pharma Ltd.0.3399+0.0219+6.89%-- 
Pre Market 0.2861 -0.0538 -15.83%
RXRXRecursion Pharmaceuticals3.02-0.29-8.76%-- 
Pre Market 2.97 -0.05 -1.66%
IOVAIovance Biotherapeutics4.66-0.08-1.69%-- 
Pre Market 4.6009 -0.0591 -1.27%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includesa small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.